A Matched-pair Analysis Comparing Systematic Prostate Biopsy by Conventional Transrectal Ultrasound-guidance Versus Software-based Predefined 3D-Guidance.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 10 01 2023
revised: 20 03 2023
accepted: 23 03 2023
medline: 23 10 2023
pubmed: 6 4 2023
entrez: 5 4 2023
Statut: ppublish

Résumé

To compare software-based three-dimensional-guided systematic prostate biopsy (3D-GSB) with conventional transrectal ultrasound-guided systematic biopsy (TGSB) regarding prostate cancer (PCa) detection rates (CDR). In total, 956 patients (200 TGSB patients and 756 3D-GSB patients) without prior positive biopsies and with a prostate-specific antigen value ≤20 ng/ml were eligible for analysis. TGSB and 3D-GSB cases were matched in a 1:1 ratio using propensity score matching with age, prostate-specific antigen, prostate volume, previous biopsy status, and suspicious palpatory finding as confounders. 3D-GSB was conducted with the semi-robotic prostate fusion-biopsy system Artemis. For each patient in both groups, SB was conducted in a similar pattern with 12 cores. All cores in 3D-GSB were automatically planned and mapped on a 3D-model as well as on the real-time transrectal ultrasound imaging. Primary end points were the clinically significant (cs) and overall CDR. Secondary end point was the cancer-positive core rate. After matching, the csCDR was not significantly different between the 3D-GSB and the TGSB groups (33.3% vs 28.8%, P = .385). Overall CDR was significantly higher for 3D-GSB compared to TGSB (55.6% vs 39.9%, P = .002). 3D-GSB detected significantly more non-significant PCa than TGSB (22.2% vs 11.1%, P = .004). In patients with PCa, the number of cancer-positive SB cores was significantly higher by TGSB (42% vs 25%, P < .001). 3D-GSB was associated with a higher CDR than TGSB. However, no significant difference was shown in detection of csPCa between both techniques. Therefore, currently, 3D-GSB does not appear to add value to conventional TGSB.

Identifiants

pubmed: 37019390
pii: S0090-4295(23)00287-X
doi: 10.1016/j.urology.2023.03.027
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-133

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Auteurs

Fabian Derigs (F)

Department of Urology and Urologic Surgery, University Medical Centre, University Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: fabian.derigs@uk-gm.de.

Karl-Friedrich Kowalewski (KF)

Department of Urology and Urologic Surgery, University Medical Centre, University Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: karl-friedrich.kowalewski@umm.de.

Friedrich Otto Hartung (FO)

Department of Urology and Urologic Surgery, University Medical Centre, University Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: friedrich.hartung@umm.de.

Frank Waldbillig (F)

Department of Urology and Urologic Surgery, University Medical Centre, University Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: frank.waldbillig@umm.de.

Manuel Neuberger (M)

Department of Urology and Urologic Surgery, University Medical Centre, University Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: manuel.neuberger@umm.de.

Jost von Hardenberg (J)

Department of Urology and Urologic Surgery, University Medical Centre, University Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: Jost.vonHardenberg@umm.de.

Niklas Westhoff (N)

Department of Urology and Urologic Surgery, University Medical Centre, University Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: niklas.westhoff@umm.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH